# Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer

> **NCT01545947** · PHASE1 · COMPLETED · sponsor: **Celgene** · enrollment: 76 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung
- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** CC-223, erlotinib
- **DRUG:** CC-223, oral azacitidine
- **DRUG:** CC-223, oral azacitidine

## Key facts

- **NCT ID:** NCT01545947
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05-01
- **Primary completion:** 2014-12-11
- **Final completion:** 2014-12-11
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2019-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01545947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01545947, "Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01545947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*